Research programme: G protein-coupled receptor 35 agonists - GlaxoSmithKline/Nxera Pharma
Alternative Names: G-protein coupled receptor 35 agonist - Nxera PharmaLatest Information Update: 28 Jan 2025
Price :
$50 *
At a glance
- Originator Sosei Heptares
- Developer GSK; Nxera Pharma
- Class Anti-inflammatories; Small molecules
- Mechanism of Action GPR35 protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gastrointestinal disorders; Inflammatory bowel diseases
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in Japan (PO)
- 28 Jan 2025 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in United Kingdom (PO)
- 28 Jan 2025 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in Japan (PO)